Reference | </br>1:Pharmacokinetics of grapiprant, a selective EP<sub>4</sub> prostaglandin PGE<sub>2</sub> receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats. Lebkowska-Wieruszewska B, De Vito V, Owen H, Poapholatep A, Giorgi M.J Vet Pharmacol Ther. 2017 Apr 29. doi: 10.1111/jvp.12414. [Epub ahead of print] PMID: 28459136 </br>2:Pharmacokinetic/pharmacodynamic evaluation of grapiprant in a carrageenan-induced inflammatory pain model in the rabbit. De Vito V, Salvadori M, Poapolathep A, Owen H, Rychshanova R, Giorgi M.J Vet Pharmacol Ther. 2016 Dec 7. doi: 10.1111/jvp.12380. [Epub ahead of print] PMID: 27925221 </br>3:Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R.J Vet Pharmacol Ther. 2016 Dec;39(6):566-571. doi: 10.1111/jvp.12306. Epub 2016 Mar 29. PMID: 27027634 </br>4:Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E<sub>2</sub> receptor antagonist, after oral administration in fasted and fed dogs. Łebkowska-Wieruszewska B, Barsotti G, Lisowski A, Gazzano A, Owen H, Giorgi M.N Z Vet J. 2017 Jan;65(1):19-23. Epub 2016 Oct 19. PMID: 27691904 </br>5:Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. Nagahisa A, Okumura T.J Vet Pharmacol Ther. 2017 Jun;40(3):285-292. doi: 10.1111/jvp.12349. Epub 2016 Sep 6. PMID: 27597397 </br>6:Safety and toxicokinetic profiles associated with daily oral administration of grapiprant, a selective antagonist of the prostaglandin E2 EP4 receptor, to cats. Rausch-Derra LC, Rhodes L.Am J Vet Res. 2016 Jul;77(7):688-92. doi: 10.2460/ajvr.77.7.688. PMID: 27347820 </br>7:A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis. Rausch-Derra L, Huebner M, Wofford J, Rhodes L.J Vet Intern Med. 2016 May;30(3):756-63. doi: 10.1111/jvim.13948. Epub 2016 Apr 13. PMID: 27075237 Free PMC Article</br>8:Detection and quantification of the selective EP4 receptor antagonist CJ-023423 (grapiprant) in canine plasma by HPLC with spectrofluorimetric detection. De Vito V, Saba A, Lee HK, Owen H, Poapolathep A, Giorgi M.J Pharm Biomed Anal. 2016 Jan 25;118:251-8. doi: 10.1016/j.jpba.2015.11.004. Epub 2015 Nov 7. PMID: 26580822 </br>9:Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. Rausch-Derra LC, Huebner M, Rhodes L.Am J Vet Res. 2015 Oct;76(10):853-9. doi: 10.2460/ajvr.76.10.853. PMID: 26413822
|